Authors

Latest:

Highlighting the Efficacy of VaxEffect With Immune Response to COVID-19 Vaccines

Renold Capocasale and Grant Morgan, PhD, PMP, both of FlowMetric Life Sciences, Inc., discuss the vaccination immune response monitoring platform VaxEffect and its clinical application, as well as potential next steps for immune response tests with other vaccines aside from COVID-19.

Joshua Hill, MD, MS

Latest:

Dr Hill on Efficacy of Dostarlimab in dMMR Locally Advanced Rectal Cancer

Joshua Hill, MD, MS, discussed the early efficacy of dostarlimab in mismatch repair–deficient locally advanced rectal cancer.

Nidia Zapata, MD

Latest:

Las Implicaciones del Estudo VIALE-A de Venetoclax Mas Azacitidina Para Paciente Inelegibles a Quimioterapia Intensiva

Nidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.

Armeen Mahvash, MD

Armeen Mahvash, MD is a Professor in the Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX.

Latest:

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Patricia A. Possik, PhD

Latest:

Dr Possik on the Importance of Diversity and Equity in Melanoma Research

Patricia A. Possik, PhD, discusses the importance of efforts to improve diversity, equity, and inclusion in melanoma research.

Bruno R. Bastos, MD, Miami Cancer Institute

Latest:

Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and Bastos

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Paul Stockhammer, MD, PhD

Latest:

Dr Stockhammer on Gene Alterations and Poor Outcomes in EGFR-Mutant Lung Cancer

Paul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.

Amer Zeidan, MBBS

Amer Zeidan, MBBS, is director of Early Therapeutics Research, director of the Leukemia and Myeloid Malignancies Program, assistant medical director of the Clinical Trials Office, and co-leader of the Leukemia and Myeloid Malignancies Clinical Research Team at Yale Cancer Center; as well as chief of the Division of Hematologic Malignancies and a professor of internal medicine (hematology) at Yale School of Medicine

Latest:

An All-Oral Regimen of Decitabine-Cedazuridine (DEC-C) Plus Venetoclax (VEN) in Patients With Newly Diagnosed AML Ineligible for Intensive Induction Chemotherapy: Results From a Phase 2 Cohort of 101 Patients

Presented by Amer Zeidan, MBBS, this OncLive Rapid Readout highlights results from the phase 2 ASCERTAIN-V trial, in which an all-oral regimen of decitabine-cedazuridine plus venetoclax achieved a 46.5% complete response rate and a median overall survival of 15.5 months in newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

Edwin Lin, MD, PhD

Latest:

Dr Lin on Defining Biomarker-Based Treatment Approaches in NSCLC

Edwin Lin, MD, PhD, discusses the utilization of antibody-drug conjugates and the importance of defining biomarker-based approaches for this treatment class in patients with non–small cell lung cancer.

Benjamin Miron, MD

Latest:

Dr Miron on the Methods of Examining Molecular Alterations in Intraductal Carcinoma of the Prostate

Benjamin Miron, MD, discusses the methods utilized in a study of molecular alterations in patients with intraductal carcinoma of the prostate and the next steps for this research.

Christian Frederick Meyer, MD, PhD, MS

Latest:

Dr. Meyer on Standard Treatment Options in Cardiac Angiosarcoma

Christian Frederick Meyer, MD, PhD, MS, discusses standard treatment options in cardiac angiosarcoma.

Ajay Choudhri, MD

Latest:

Dr. Choudhri on the Impact of Artificial Intelligence in Cancer Care

Ajay Choudhri, MD, discusses the impact of developments in artificial intelligence in cancer care.

Goutham Narla, MD, PhD

Latest:

Dr. Narla on Advances Made With Precision Medicine in Oncology

Goutham Narla, MD, PhD, discusses advances made with precision medicine in oncology.

Nicole O. Williams, MD

Latest:

Dr. Williams on the Role of PI3K Inhibitors in HR+/HER2- Breast Cancer

Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Jeffrey V. Matous, MD

Latest:

Dr Matous on the Use Talquetamab/Pomalidomide in Relapsed/Refractory Multiple Myeloma

Jeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.

Krzysztof Jamroziak, PhD

Krzysztof Jamroziak, PhD, is a hematology specialist in the Department of Hematology, Transplantology, and Internal Medicine, as well as the acting deputy head in the Department of General Hematology at the Medical University of Warsaw.

Latest:

Dr Jamroziak on Daratumumab vs Observation in Multiple Myeloma With MRD Reappearance

Krzysztof Jamroziak, PhD, discusses findings from the phase 2 PREDATOR-MRD trial (NCT03697655).

Timothy Yap, MBBS, PhD, FRCP

Latest:

Dr Yap on the Continued Investigation of Saruparib in Advanced Solid Tumors

Timothy Yap, MBBS, PhD, FRCP, discusses next steps for investigating saruparib in advanced solid tumors with genetic mutations, including prostate cancer.

Scott S. Tykodi, MD, PhD

Scott Tykodi, MD, PhD, is an associate professor in the Clinical Research Division and an affiliate investigator in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center.

Latest:

Dr Tykodi on the Current Limitations of Cabozantinib-Based Triplets in Advanced RCC

Scott Tykodi, MD, PhD, discusses the challenges with developing effective, less toxic triplet regimens for patients with advanced RCC.

Justine Yang Bruce, MD

Justine Yang Bruce, MD, is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine at the University of Wisconsin, as well as the director of the VA Medical Oncology Clinical Research Program and dhair of the Protocol Review and Monitoring Committee at the University of Wisconsin Carbone Cancer Center

Latest:

Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

Dr Bruce discusses treatment strategies for nasopharyngeal cancer, including how first-line toripalimab plus chemotherapy has shown improved OS.

Gustavo Rivero, MD

Gustavo Rivero, MD, is the director of translational research for myeloid disorders at Tampa General Hospital Cancer Institute in Florida and an associate professor of hematology/oncology.

Latest:

Targeting Menin: A New Frontier in Treating Refractory Leukemias

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.